GSK's shingles virus vaccine has been approved in Korea. As a result, competition between MSD and SK Bioscience is expected to take place for the lead in the market. The MFDS approved GSK's gene recombinant shingles vaccine Shingrix on the 6th.

This product is a vaccine used to prevent shingles in adults over the age of 50 and those who are expected to have high risk of shingles due to disease or treatment or immunosuppressants.

It is a product that injects 0.5ml IM once and twice every two months. Shingrix was approved by the U.S. FDA in October 2017. In the United States, it is recognized for its product power by beating its competitors and ranking first in market share within a year o